drugset / Trial / NCT05557292
RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma
Phase 1
Terminated
7 enrolled
Nicholas Butowski
National Cancer Institute (NCI) · collabRevolution Medicines, Inc. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This phase I/Ib trial tests the side effects, best dose, tolerability, and effectiveness of RMC-5552 in treating patients with glioblastoma that has come back (recurrent). RMC-5552 is a type of medicine called an mechanistic target of rapamycin (mTOR) inhibitor. These types of drugs prevent the formation of a specific group of proteins called mTOR. This protein controls cancer cell growth, and the study doctors believe stopping mTOR from forming may help to kill tumor cells.
Timeline
- Start
- 2023-04-03
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Outcome
Outcome not reported
Stopped: “Drug no longer provided by sponsor”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RMC-5552 | Unknown | 6 mg | Intravenous |
| Subject | RMC-5552 | Unknown | 12 mg | Intravenous |